Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3010% below fair value
$20.82+0.15 (+0.73%)
Close on Nov 13, 2026Market cap $23.91BP/E –Yield 2.31%
Viatris ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Viatris's ebitda for the twelve months ending Sep 30, 2026 was $2.81B, up 2102.2% year over year. For fiscal 2025 it was $135.20M, down 95.3% from the year before. The highest annual figure on record is $4.64B in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.20M | -95.3% |
| FY2024 | Dec 31, 2024 | $2.90B | -17.2% |
| FY2023 | Dec 31, 2023 | $3.51B | -24.5% |
| FY2022 | Dec 31, 2022 | $4.64B | +3.8% |
| FY2021 | Dec 31, 2021 | $4.47B | +123.0% |
| FY2020 | Dec 31, 2020 | $2.01B | -26.7% |
| FY2019 | Dec 31, 2019 | $2.73B | -9.3% |
| FY2018 | Dec 31, 2018 | $3.02B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $958.70M | +10.5% |
| Q2 FY2026 | Jun 30, 2026 | $678.60M | -25.5% |
| Q1 FY2026 | Mar 31, 2026 | $596.40M | – |
| Q4 FY2025 | Dec 31, 2025 | $574.10M | +1.4% |
| Q3 FY2025 | Sep 30, 2025 | $867.30M | -3.2% |
| Q2 FY2025 | Jun 30, 2025 | $911.30M | +66.8% |
| Q1 FY2025 | Mar 31, 2025 | -$2.22B | -347.8% |
| Q4 FY2024 | Dec 31, 2024 | $566.40M | +198.3% |
| Q3 FY2024 | Sep 30, 2024 | $895.60M | -20.8% |
| Q2 FY2024 | Jun 30, 2024 | $546.40M | -48.3% |
| Q1 FY2024 | Mar 31, 2024 | $894.90M | -20.8% |
| Q4 FY2023 | Dec 31, 2023 | $189.90M | -71.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.13B | -10.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.06B | -16.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.13B | -21.7% |
| Q4 FY2022 | Dec 31, 2022 | $668.50M | -0.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.26B | -8.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.27B | +0.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.44B | +24.8% |
| Q4 FY2021 | Dec 31, 2021 | $672.20M | +833.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.37B | +75.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.27B | +130.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.16B | +92.8% |
| Q4 FY2020 | Dec 31, 2020 | $72.00M | – |
| Q3 FY2020 | Sep 30, 2020 | $783.70M | – |
| Q2 FY2020 | Jun 30, 2020 | $549.90M | – |
| Q1 FY2020 | Mar 31, 2020 | $599.70M | – |
See a number that looks wrong?